Results 31 to 40 of about 17,496 (173)

Nanocarriers to enhance solubility, bioavailability, and efficacy of artemisinins

open access: yes, 2020
The therapeutic potential of artemisinin (ART) and its derivatives (ARTs) is not limited to malaria but has been recently expanded to other infections with protozoans, trematodes, or viruses as well as to cancer.
A. Bilia   +3 more
semanticscholar   +1 more source

Quantifying the pharmacology of antimalarial drug combination therapy. [PDF]

open access: yes, 2016
Most current antimalarial drugs are combinations of an artemisinin plus a 'partner' drug from another class, and are known as artemisinin-based combination therapies (ACTs). They are the frontline drugs in treating human malaria infections.
Hodel, Eva Maria
core   +1 more source

Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria [PDF]

open access: yes, 2008
Besides existing artemisinin-based combination therapies, alternative safe, effective and affordable drug combinations against falciparum malaria are needed. Methylene blue (MB) was the first synthetic antimalarial drug ever used, and recent studies have
Coulibaly, Boubacar   +10 more
core   +1 more source

Do Health Workers' Preferences Influence their Practices? Assessment of Providers' Attitude and Personal use of new Treatment Recommendations for Management of Uncomplicated Malaria, Tanzania. [PDF]

open access: yes, 2012
\ud \ud Due to growing antimalarial drug resistance, Tanzania changed malaria treatment policies twice within a decade. First in 2001 chloroquine (CQ) was replaced by sulfadoxine-pyrimethamine (SP) for management of uncomplicated malaria and by late 2006,
Khatib, Rashid A   +2 more
core   +3 more sources

Artemisinin: current status

open access: yesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
The compounds derived from the Chinese medicinal plant qinghao (Artemisia annua) are the most rapidly acting of all antimalarial drugs. They are effective when given parenterally, orally or by suppository. No serious adverse effect has yet been reported in humans.
Nicholas J. White   +2 more
openaire   +3 more sources

In silico Drug Repurposing of FDA-Approved Artemisinins as Potent Chemotherapeutics Targeting Bcl-2, CDK-6 & VEGFR-2: Density Functional Exploration and Molecular Docking Study

open access: yes, 2020
The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. This paper focuses on drug repurposing of artemisinin and its derivatives (artenimol, artemether, artemotil, and
S. Parveen
semanticscholar   +1 more source

More than anti-malarial agents: therapeutic potential of artemisinins in neurodegeneration

open access: yesNeural Regeneration Research, 2019
Artemisinin, also called qinghaosu, is originally derived from the sweet wormwood plant (Artemisia annua), which is used in traditional Chinese medicine. Artemisinin and its derivatives (artemisinins) have been widely used for many years as anti-malarial
B. Lu   +4 more
semanticscholar   +1 more source

Exploration of in Vivo Efficacy of Artemether-Lumefantrine Against Uncomplicated Plasmodium Falciparum Malaria in Under Fives in Tabora Region, Tanzania. [PDF]

open access: yes, 2013
Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006. Recently, there was an anecdotal report on high malaria recurrence rate following AL treatment in in the (urban and peri-urban), western part of Tanzania.
Hulser, Ruth   +5 more
core   +3 more sources

Artemisinin-based combinations

open access: yesCurrent Opinion in Infectious Diseases, 2005
Artemisinin-based combination treatments have been the mainstay of treatment for falciparum malaria in Southeast Asia for more than 10 years and are now increasingly recommended as first-line treatment throughout the rest of the world.A large multicentre randomised trial conducted in East Asia has shown a 35% reduction in mortality from severe malaria ...
Ashley, E, White, N
openaire   +4 more sources

Development of an Organoautocatalyzed Double σ‐Bond C(sp2)‐N Transamination Metathesis Reaction

open access: yesAngewandte Chemie, EarlyView.
Organoautocatalyzed transamination metathesis of cyclic tertiary amines is disclosed as a high‐yielding, scalable reaction that proceeds under mild, catalyst‐free conditions. It operates via a multi‐step domino reaction mechanism, where an in situ‐formed pyrrolidinium salt functions as a HBD organoautocatalyst.
Volker Klein   +7 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy